1,086,830 NewAmsterdam Pharma Company N.V. $NAMS Shares Sold by Aberdeen Group plc

Aberdeen Group plc lowered its holdings in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS – Free Report) by 98.6% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 15,955 shares of the company’s stock after selling 1,086,830 shares during the quarter. Aberdeen Group plc’s holdings in NewAmsterdam Pharma were worth $388,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Bank of America Corp DE grew its holdings in shares of NewAmsterdam Pharma by 84.4% during the first quarter. Bank of America Corp DE now owns 847,089 shares of the company’s stock worth $27,115,000 after buying an additional 387,698 shares during the last quarter. Frazier Life Sciences Management L.P. increased its position in NewAmsterdam Pharma by 6.8% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 18,088,902 shares of the company’s stock valued at $613,033,000 after acquiring an additional 1,145,128 shares during the period. Squarepoint Ops LLC raised its stake in NewAmsterdam Pharma by 113.9% during the 2nd quarter. Squarepoint Ops LLC now owns 92,026 shares of the company’s stock valued at $3,119,000 after acquiring an additional 49,005 shares during the last quarter. Stempoint Capital LP raised its stake in NewAmsterdam Pharma by 147.1% during the 1st quarter. Stempoint Capital LP now owns 180,658 shares of the company’s stock valued at $5,783,000 after acquiring an additional 107,552 shares during the last quarter. Finally, Alps Advisors Inc. raised its stake in NewAmsterdam Pharma by 34.1% during the 3rd quarter. Alps Advisors Inc. now owns 158,398 shares of the company’s stock valued at $3,852,000 after acquiring an additional 40,253 shares during the last quarter. Institutional investors and hedge funds own 89.89% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on NAMS shares. Royal Bank Of Canada decreased their price objective on NewAmsterdam Pharma from $50.00 to $42.00 and set an “outperform” rating on the stock in a report on Monday, October 5th. Wall Street Zen raised shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Sunday, November 1st. Needham & Company LLC lowered their target price on shares of NewAmsterdam Pharma from $48.00 to $46.00 and set a “buy” rating for the company in a report on Thursday, November 5th. HC Wainwright reaffirmed a “buy” rating and set a $52.00 price target on shares of NewAmsterdam Pharma in a research report on Tuesday, September 8th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $49.82.

Check Out Our Latest Report on NAMS

Insider Transactions at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, Director John W. Smither sold 1,600 shares of the business’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $25.32, for a total transaction of $40,512.00. Following the sale, the director directly owned 8,760 shares in the company, valued at approximately $221,803.20. The trade was a 15.44% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Michael H. Davidson purchased 10,000 shares of the company’s stock in a transaction on Monday, September 14th. The shares were bought at an average price of $22.65 per share, for a total transaction of $226,500.00. Following the completion of the transaction, the chief executive officer directly owned 792,923 shares in the company, valued at $17,959,705.95. This represents a 1.28% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders sold 176,846 shares of company stock worth $4,661,919. Company insiders own 12.74% of the company’s stock.

NewAmsterdam Pharma Trading Down 5.6%

NewAmsterdam Pharma stock opened at $18.41 on Friday. The stock has a market cap of $2.21 billion, a P/E ratio of -10.89 and a beta of 0.15. The stock has a 50 day moving average of $21.09 and a 200-day moving average of $28.87. NewAmsterdam Pharma Company N.V. has a 52 week low of $17.90 and a 52 week high of $42.21.

NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.33. The firm had revenue of $19.16 million during the quarter, compared to analyst estimates of $8.82 million. NewAmsterdam Pharma had a negative return on equity of 31.39% and a negative net margin of 789.95%. As a group, equities analysts predict that NewAmsterdam Pharma Company N.V. will post -1.48 earnings per share for the current fiscal year.

About NewAmsterdam Pharma

(Free Report)

NewAmsterdam Pharma is a biopharmaceutical company focused on developing oral treatments for cardiometabolic diseases, particularly conditions involving elevated cholesterol and cardiovascular risk. The company’s lead investigational medicine is obicetrapib, an oral inhibitor of cholesteryl ester transfer protein (CETP) being studied to lower LDL cholesterol. NewAmsterdam has evaluated obicetrapib both on its own and in combination with ezetimibe, including in clinical studies involving people with inherited high cholesterol or established cardiovascular disease whose cholesterol remains elevated despite existing treatment.

Featured Stories

Institutional Ownership by Quarter for NewAmsterdam Pharma (NASDAQ:NAMS)

Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.